



**IPO NOTE**

**Nephrocare Health  
Services Ltd.**

**09th Dec 2025.**

## Company Overview

Nephrocare Health Services offers comprehensive dialysis care through its network of clinics, from diagnosis and treatment to wellness programs, including haemodialysis, home and mobile dialysis, and a pharmacy. The company also provides holiday dialysis, on-call dialysis, and dialysis-on-wheels services to its patients in India. The company is India's largest dialysis service provider, based on the number of patients served, clinics, cities covered, treatments performed, revenue, and EBITDA in FY25. Further, the company is 4.4 times the size of the next-largest organized dialysis provider in India, based on operating revenue in FY24. In FY25, the company served 29,281 patients and completed 2,885,450 treatments in India, which represented ~10% of the total dialysis patients in India. The company operates 519 clinics, forming India's most extensive dialysis network, with a presence across 288 cities in 21 States and 4 Union Territories as of September 30, 2025. 77.4% of its clinics are located in tier II and tier III cities and towns. As of September 30, 2025, 80 clinics operated through greenfield, 259 through brownfield, and 180 via PPP collaborations. The company has partnered with leading hospital chains in India, including Max Super Specialty Hospital, Fortis Escorts Hospitals, Care Hospitals, Wockhardt Hospitals, Paras Healthcare, The Calcutta Medical Research Institute, Jehangir Hospital and Grand Medical Foundation (Ruby Hall) to operate specific dialysis clinics. The company is the leader in dialysis services in FY25, with a market share of over 50% in the organised market (by number of treatments) and ~50% in revenue generated by organized dialysis service providers. The company's clinics are accredited by leading bodies in India, with 145 of its dialysis clinics accredited by NABH and three by JCI as of September 30, 2025. The company also complies with ISO standards ISO 9001:2015 for quality management systems.

## Objects of the issue

Out of the total issue size of Rs. 871 crores, Rs. 518 crores comprises OFS.

The company proposes to utilize net proceeds from the issue towards the following objects:

- Capital expenditure by company for opening new dialysis clinics in India and;
- Pre-payment, or scheduled repayment, in full or part, of certain borrowings availed by company; and
- General corporate purposes.

## Investment Rationale

### Strong market presence as India and Asia's largest dialysis provider

The company is India's largest dialysis service provider in terms of the number of patients served, clinics, cities covered, treatments performed, revenue, and EBITDA (excluding other income) in FY25, and it is 4.4 times the size of the next largest organized dialysis provider in India in terms of operating revenue in FY24. The company was also the largest dialysis service provider in Asia in 2025 and the fifth-largest globally based on the number of treatments performed in FY25. In India, the company is the leader in dialysis services in FY25, with a market share of over 50% in the organized dialysis market (by number of treatments) and ~50% in revenue generated by organized dialysis service providers. As of September 30, 2025, the company has performed over 1.87 million treatments, with the number of treatments growing at a CAGR of 20.1% between FY23 and FY25. Additionally, as of September 30, 2025, the company had 5,562 dialysis machines, up from 5,068, 4,714, and 3,662 as of March 31, 2025, March 31, 2024, and March 31, 2023, respectively. As of September 30, 2025, the company operated clinics in 3 countries other than India. The company commenced international operations in 2018 with its entry into Nepal, an extension of its cluster-based approach in India. The company entered the Philippine market in October 2020, following its acquisition of a majority stake in Royal Care Dialysis Centre Inc. (RCDC) and Asialife Healthcare Corp (Asialife). Through these acquisitions, the company gained access to RCDC's and Asialife's network of six clinics across the Philippines. Over the next 2 years, the company subsequently acquired 100% ownership of RCDC and expanded its footprint to 10 clinics. As of September 30, 2025, the company operated 51 clinics in the Philippines. The company was the 3rd-largest dialysis service provider in the Philippines by the number of clinics in 2024. The company won a USD 75+ million PPP tender issued by the Ministry of Health, Republic of Uzbekistan, to establish four clinics, including a 165-bed dialysis clinic in Tashkent, the largest dialysis clinic globally.

### Scale, coupled with an asset-light model, drives cost efficiencies and operational excellence

The company has expanded from a single clinic in India in 2010 to 519 clinics across India, Nepal, the Philippines, and Uzbekistan as of September 30, 2025, with a presence in 328 cities. Its growth strategy combines greenfield and brownfield operations with PPP collaborations, enabling efficient scaling and diverse patient coverage. As of September 30, 2025, 80 clinics operated through greenfield, 259 through brownfield, and 180 via PPP collaborations. The company follows an asset-light model, enabling lower establishment and operating costs compared to tertiary care and other single-speciality services. As of September 30, 2025, 52.4%

## Issue Details

Offer Period 10th Dec. 2025 - 12th Dec. 2025

Price Band Rs. 154 to Rs. 162

Bid Lot 92

Listing BSE & NSE

Issue Size (no. of shares in Crs) 4.75

Issue Size (Rs. in Crs) 920

Face Value (Rs.) 2

## Issue Structure

QIB 50%

NIB 15%

Retail 35%

BRLM Nuvama Wealth Management Ltd.; CLSA India Private Ltd.; DAM Capital Advisors Ltd.; Intensive Fiscal Services Private Ltd.

Registrar KFin Technologies Ltd.

| Particulars               | Pre Issue %    | Post Issue %   |
|---------------------------|----------------|----------------|
| Promoter & Promoter Group | 95.55%         | 82.89%         |
| Public                    | 4.45%          | 17.11%         |
| <b>Total</b>              | <b>100.00%</b> | <b>100.00%</b> |

(Assuming issue subscribed at higher band)

of its 519 clinics operate on a revenue-sharing model with limited space investment, reflecting its commitment to lean operations. Initiatives such as standardized clinic formats, an in-house projects team, and an efficient supply chain have helped reduce capital expenditure and keep establishment costs low. In the 6 months ended September 30, 2025, and FY25, FY24, and FY23, capital expenditure per clinic was Rs. 1.0 crores, Rs. 1.4 crores, Rs. 1.7 crores, and Rs. 1.1 crores, respectively. The company uses a cluster-based approach to expand its network, starting with clinics in densely populated areas and then growing within cities and nearby towns. Expansion is guided by catchment demographics, market dynamics, and backend infrastructure, with clinic selection based on demand-supply gaps, nephrologist availability, dialysis volumes, government schemes, and due diligence. This approach has enabled operations in non-metro, tier II, and tier III locations, improving accessibility. As of September 30, 2025, the company had 128 clinics in tier II and 234 in tier III cities.

## Valuation

The company is India's largest dialysis service provider, with market leadership across key metrics including patients served, clinics, cities covered, treatments performed, revenue, and EBITDA in FY25. Its scale advantage is significant, being 4.4 times larger than the next-largest organized player in terms of operating revenue in FY24. With operations spanning India and international markets, including Nepal, the Philippines (51 clinics), Uzbekistan, and KSA, the company has established itself as the largest dialysis chain in Asia and the fifth-largest globally, based on treatments performed in FY25. The company has also built a highly scalable hub-and-spoke model, anchored in an asset-light approach, in which it partners with hospitals and public health authorities to expand its clinic footprint without significant upfront capital. This allows rapid market entry, superior cost efficiency, and substantial operating leverage as patient volumes scale. Its international acquisitions have enabled the company to diversify revenue streams, deepen regional penetration, and replicate its successful cluster-based India strategy across Asia. India's dialysis market is structurally expanding due to rising CKD prevalence, increasing prevalence of lifestyle diseases, limited access to renal care in Tier-II/III cities, and low penetration of organized dialysis networks. The organized dialysis segment is rapidly gaining share as government programs, insurance coverage, and PPP-driven models expand patient access to affordable, reliable services. On the financial front, the company has demonstrated CAGR growth of 31.5%/85.2% in Revenue/EBITDA between FY23 and FY25, driven by rapid network expansion, rising treatment volumes, and improving revenue per treatment, supported by acquisitions, new clinic openings, and scale benefits. Overall, the company is well-positioned to sustain its growth trajectory, driven by continued clinic additions, further penetration into underserved regions, and scaling of international operations. **At the upper end of the price band at Rs. 460, the company is valued at a P/E multiple of 57.4x FY25 earnings. We, thus, recommend a "SUBSCRIBE" rating for this issue.**

## Key Risks

- A significant share of company's revenue comes from captive clinics within private hospitals. Any cancellation or non-renewal of these contracts could materially disrupt operations and adversely impact our revenue and financial performance.
- A meaningful portion of company's revenue is derived from PPP contracts awarded through competitive government bidding. Any inability to qualify for, win, or renew such tenders could reduce revenue visibility and adversely affect our business prospects, financial performance, and cash flows.
- The company exposed to operational, medical, legal, and reputational risks inherent in delivering dialysis services. Any failure to maintain required quality standards could lead to patient harm, litigation, and reputational damage, materially impacting operations and financial performance.

## Income Statement (Rs. in Crores)

| Particulars                     | FY23       | FY24       | FY25       | H1FY26     |
|---------------------------------|------------|------------|------------|------------|
| <b>Revenue:</b>                 |            |            |            |            |
| Revenue from operations         | 437        | 566        | 756        | 474        |
| <b>Total revenue</b>            | <b>437</b> | <b>566</b> | <b>756</b> | <b>474</b> |
| <b>Expenses:</b>                |            |            |            |            |
| Cost of material Consumed       | 143        | 169        | 194        | 109        |
| Employee Benefits               | 97         | 91         | 123        | 83         |
| Healthcare professional fees    | 31         | 59         | 90         | 52         |
| Hospital fees                   | 48         | 56         | 68         | 39         |
| Other Expenses                  | 71         | 90         | 114        | 80         |
| <b>Total expenses</b>           | <b>389</b> | <b>465</b> | <b>589</b> | <b>362</b> |
| <b>EBITDA</b>                   | <b>49</b>  | <b>101</b> | <b>167</b> | <b>111</b> |
| Depreciation & amortization     | 47         | 56         | 72         | 43         |
| <b>EBIT</b>                     | <b>2</b>   | <b>45</b>  | <b>94</b>  | <b>69</b>  |
| Finance costs                   | 16         | 20         | 21         | 51         |
| Other Income                    | 6          | 9          | 14         | 10         |
| <b>PBT</b>                      | <b>-9</b>  | <b>33</b>  | <b>87</b>  | <b>28</b>  |
| Current Tax                     | 0          | 2          | 17         | 17         |
| Deferred tax expenses (benefit) | 3          | -4         | 3          | -4         |
| <b>Total tax expenses</b>       | <b>3</b>   | <b>-2</b>  | <b>20</b>  | <b>14</b>  |
| <b>PAT</b>                      | <b>-12</b> | <b>35</b>  | <b>67</b>  | <b>14</b>  |
| Diluted EPS                     | -1.5       | 4.4        | 8.0        | 1.6        |

Source:RHP,StoxBox

## Cash Flow Statement (Rs. in Crores)

| Particulars   | FY23       | FY24       | FY25        | H1FY26      |
|---|------------|------------|-------------|-------------|
| <b>Cash Flow from operating activities</b>                      | <b>11</b>  | <b>72</b>  | <b>135</b>  | <b>38</b>   |
| <b>Cash flow from/(used in) investing activities</b>            | <b>-78</b> | <b>-51</b> | <b>-125</b> | <b>-114</b> |
| <b>Net cash flows (used in) / from financing activities</b>     | <b>60</b>  | <b>27</b>  | <b>54</b>   | <b>17</b>   |
| <b>Net increase/(decrease) in cash and cash equivalents</b>     | <b>-7</b>  | <b>48</b>  | <b>65</b>   | <b>-59</b>  |
| <b>Cash and cash equivalents at the beginning of the period</b> | <b>19</b>  | <b>14</b>  | <b>61</b>   | <b>126</b>  |
| <b>Cash and cash equivalents at the end of the period</b>       | <b>14</b>  | <b>61</b>  | <b>126</b>  | <b>83</b>   |

Source:RHP,StoxBox

## Balance Sheet (Rs. in Crores)

| Particulars                           | FY23       | FY24       | FY25       | H1FY26       |
|---------------------------------------|------------|------------|------------|--------------|
| <b>Assets</b>                         |            |            |            |              |
| <b>Non-Current Assets</b>             |            |            |            |              |
| Property, plant and equipment         | 185        | 263        | 278        | 304          |
| Capital Work in progress              | 32         | 1          | 6          | 11           |
| Right-of-use of assets                | 34         | 41         | 46         | 69           |
| Goodwill                              | 19         | 41         | 56         | 76           |
| Other intangible assets               | 1          | 11         | 17         | 25           |
| Intangible assets under development   | 2          | 0          | 0          | 0            |
| <b>Financial Assets</b>               |            |            |            |              |
| (i) Other financial assets            | 45         | 19         | 19         | 11           |
| Deferred tax assets (net)             | 17         | 24         | 21         | 34           |
| Other tax assets (net)                | 5          | 11         | 1          | 2            |
| Other non current assets              | 2          | 5          | 8          | 9            |
| <b>Total Non Current assets</b>       | <b>342</b> | <b>416</b> | <b>451</b> | <b>542</b>   |
| <b>Current Assets</b>                 |            |            |            |              |
| Inventories                           | 26         | 26         | 27         | 34           |
| <b>Financial Assets</b>               |            |            |            |              |
| (i) Investments                       | 0          | 0          | 51         | 123          |
| (ii) Trade Receivables                | 159        | 203        | 266        | 329          |
| (iii) Cash and Cash equivalents       | 14         | 61         | 126        | 83           |
| (iv) Bank balances other than cash    | 0          | 0          | 30         | 31           |
| (v) Other financial assets            | 116        | 86         | 29         | 3            |
| Other current assets                  | 10         | 14         | 17         | 49           |
| <b>Total Current Assets</b>           | <b>324</b> | <b>390</b> | <b>545</b> | <b>651</b>   |
| <b>Total Assets</b>                   | <b>666</b> | <b>806</b> | <b>996</b> | <b>1,194</b> |
| <b>Equity and Liabilities</b>         |            |            |            |              |
| Equity Share Capital                  | 2          | 2          | 2          | 4            |
| Instruments entirely equity in nature | 3          | 3          | 4          | 9            |
| Other Equity                          | 383        | 409        | 579        | 704          |
| <b>Total Equity</b>                   | <b>389</b> | <b>414</b> | <b>584</b> | <b>717</b>   |
| <b>Non-Current Liabilities</b>        |            |            |            |              |
| <b>Financial Liabilities</b>          |            |            |            |              |
| (i) Borrowings                        | 81         | 123        | 96         | 45           |
| (ii) Lease Liabilities                | 13         | 19         | 25         | 44           |
| (iii) Other financial liabilities     | 4          | 4          | 1          | 1            |
| Provisions                            | 4          | 3          | 5          | 5            |
| Deferred tax liabilities (net)        | 0          | 0          | 2          | 15           |
| <b>Total Non-Current Liabilities</b>  | <b>103</b> | <b>150</b> | <b>128</b> | <b>109</b>   |
| <b>Current Liabilities</b>            |            |            |            |              |
| <b>Financial Liabilities</b>          |            |            |            |              |
| (i) Borrowings                        | 115        | 120        | 130        | 162          |
| (ii) Lease Liabilities                | 4          | 6          | 7          | 11           |
| (iii) Trade payables                  | 43         | 71         | 113        | 129          |
| (iv) Other financial liabilities      | 8          | 41         | 22         | 49           |
| Other current liabilities             | 3          | 4          | 5          | 4            |
| Provisions                            | 1          | 1          | 2          | 2            |
| Current tax liabilities (net)         | 0          | 0          | 5          | 10           |
| <b>Total Current Liabilities</b>      | <b>175</b> | <b>243</b> | <b>284</b> | <b>367</b>   |
| <b>Total Liabilities</b>              | <b>278</b> | <b>392</b> | <b>412</b> | <b>477</b>   |
| <b>Total Equity and Liabilities</b>   | <b>666</b> | <b>806</b> | <b>996</b> | <b>1,194</b> |

Source: RHP,StoxBox

## Disclaimer Appendix

Analyst (s) holding in the Stock : Nil

### Analyst (s) Certification :

We analysts and the authors of this report, hereby certify that all of the views expressed in this research report accurately reflect our personal views about any and all of the subject issuer (s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation (s) or view (s) in this report. Analysts aren't registered as research analysts by FINRA and might not be an associated person of the BP Equities Pvt. Ltd. (Institutional Equities).

### General Disclaimer :

This report has been prepared by the research department of BP EQUITIES Pvt. Ltd, is for information purposes only. This report is not construed as an offer to sell or the solicitation of an offer to buy or sell any security in any jurisdiction where such an offer or solicitation would be illegal.

BP EQUITIES Pvt. Ltd have exercised due diligence in checking the correctness and authenticity of the information contained herein, so far as it relates to current and historical information, but do not guarantee its accuracy or completeness. The opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time. Prospective investors are cautioned that any forward looking statement are not predictions and are subject to change without prior notice. Recipients of this material should rely on their own investigations and take their own professional advice.

BP EQUITIES Pvt. Ltd or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report.

BP EQUITIES Pvt. Ltd. or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations. BP EQUITIES Pvt. Ltd and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by any person in any locality, state and country or other jurisdiction where such distribution, publication or use would be contrary to the law or regulation or would subject to BP EQUITIES Pvt. Ltd or any of its affiliates to any registration or licensing requirement within such jurisdiction.

Stobox is a brand of BP Equities Pvt Ltd and BP Equities Pvt Ltd is a SEBI Registered broker.

BP Equities Pvt Ltd – SEBI Regn No: INZ000176539 (BSE/NSE), INZ000030431 (MCX/NCDEX), IN-DP-CDSL-183-2002 (CDSL), INH000000974 (Research Analyst) CIN: U45200MH1994PTC081564BP Comtrade Pvt Ltd – SEBI Regn No: INZ000030431 CIN: U45200MH1994PTC081564

For complaints, send email on investor@bpwealth.com.

### Corporate Office :

4<sup>th</sup> floor, Rustom Bldg, 29, Veer Nariman Road, Fort, Mumbai-400001  
Phone- +91 22 6159 6464 | Fax:+91 22 6159 6160 | <https://stobox.in/>

### Registered Office :

24/26, 1st floor, , Cama Building, Dalal street, Fort, Mumbai-40000



## Download the App Now!



Follow us on

